drugset / Trial / NCT04032860

RCT of Different Effects of Nucleot(s)Ide Analogues on the Prognosis of HBV-HCC Patients After Curative Resection

NCT04032860

Phase 4 Unknown 104 enrolled West China Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

In Asia, hepatocellular carcinoma (HCC) commonly occurred in the underlying hepatitis B virus (HBV)-related liver disease.Curative therapies could improve the prognosis of HCC patients. However, tumor recurrence after curative therapy remains high with a 5-year recurrence rate \>70%.The risk for HCC development is increased for patient with HBV infection,but there was no consensus about which kind of oral antiviral treatment was the best option in the prevention of HBV related HCC recurrence after curative treatment.Therefore, we conducted this study to investigate the different effects of nucleotides(TDF) and nucleosides(ETV) on the prognosis of HBV-related HCC after curative resection.

Timeline

Start
2017-07-01
Primary completion
2022-07-01
Completion
2026-07-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Entecavir Small molecule 0.5 mg Oral
Subject Tenofovir disoproxil fumarate Small molecule 300 mg Oral